Targeted Drug Therapy for Pancreatic Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing four experimental drugs to see if they can help treat pancreatic cancer. The drugs work by blocking important processes that cancer cells need to grow and survive. The trial focuses on patients with pancreatic cancer who do not respond well to standard treatments. Gemcitabine was the first agent investigated for its potential to improve symptoms and overall well-being in pancreatic cancer patients.
Will I have to stop taking my current medications?
The trial requires a 10-day period without taking any previous cancer treatments before starting the study drugs. Additionally, you cannot take certain medications that affect liver enzymes (CYP3A) or those that prolong the QT interval (a heart rhythm measure).
What evidence supports the effectiveness of the drug combination including Cobimetinib, Cotellic, LY3214996, Temuterkib, Olaparib, Lynparza, and Onvansertib for pancreatic cancer?
There is some evidence that the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib showed a positive tumor response in a patient with a specific type of advanced pancreatic cancer. However, overall, targeted therapies have not shown significant benefits for most pancreatic cancer patients, and the effectiveness of the specific drug combination in the trial is not directly supported by the available research.12345
Is targeted drug therapy for pancreatic cancer generally safe in humans?
How is the drug combination of Cobimetinib, LY3214996, Olaparib, and Onvansertib unique for treating pancreatic cancer?
This drug combination is unique because it targets specific pathways and molecules involved in the growth and spread of pancreatic cancer cells, unlike traditional chemotherapy that attacks all rapidly dividing cells. Cobimetinib, for example, is a MEK inhibitor that has shown promise in targeting specific mutations in pancreatic cancer, offering a more tailored approach to treatment.59101112
Eligibility Criteria
Adults (18+) with pancreatic cancer, either resectable or metastatic adenocarcinoma, who can consent to treatment and biopsies. They may be new to treatment or have had prior therapy with a specific washout period. Good organ function is required, and they must not be pregnant or breastfeeding. Contraception use is necessary for participants of childbearing potential.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive assigned study agent (cobimetinib, olaparib, onvansertib, azenosertib, AZD5305, or tremelimumab) for 10 days, followed by biopsy or surgery
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cobimetinib (MEK/ERK Inhibitor)
- LY3214996 (MEK/ERK Inhibitor)
- Olaparib (PARP Inhibitor)
- Onvansertib (Other)
Cobimetinib is already approved in European Union, United States, Canada, Switzerland, Japan for the following indications:
- Melanoma
- Melanoma
- Melanoma
- Melanoma
- Melanoma